To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Brielle Benyon
The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.
Brielle Benyon
The Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) – the first biosimilar of Rituxan (rituximab) – to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL).
Tommy Thompson
Adaptive clinical trials are poised to deliver hope to patients with pancreatic cancer.
Brielle Benyon and Katie Kosko
November is Lung Cancer Awareness Month, and our Lung Cancer Special Issue is offering new insights into the treatment of the disease.
Katie Kosko
Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.
Kristie L. Kahl
Despite associated toxicities, cisplatin chemotherapy induced superior efficacy compared with a new alternative among patients with HPV-positive oropharyngeal carcinoma.
Jason M. Broderick
The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Brielle Benyon
A smartphone app helped significantly reduce pain and hospital visits for patients with metastatic solid tumors.
Jessica Skarzynski
Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.
Jessica Skarzynski and Kristie L. Kahl
The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other